The new data gives BMS an opportunity to extend its lead over Cytokinetics, in pursuit of mavacamten with its rival cardiac myosin inhibitor CK-274 which cleared a phase 2 trial last year and is ...

Set against the dramatic backdrop of towering dinosaur exhibits, the event will feature ... by generous sponsors including annual partners Cytokinetics, Harmony Biosciences, and Scientific ...

Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team ...

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...

Cytokinetics, Incorporated has a one year low of $39.81 and a one year high of $75.71. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28.

Investing.com -- Shares of Cytokinetics (NASDAQ: NASDAQ:CYTK) climbed 11% after Edgewise Therapeutics reported results for its treatment of hypertrophic cardiomyopathy (HCM), which led to a 28% ...

View Our Latest Stock Analysis on Cytokinetics Cytokinetics Stock Performance CYTK opened at $43.19 on Monday. Cytokinetics has a 52-week low of $40.53 and a 52-week high of $75.71. The company ...

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to participate in ...

Cytokinetics (NASDAQ:CYTK) added ~10% in the premarket on Wednesday after its rival Edgewise Therapeutics (NASDAQ:EWTX) posted topline data from a mid-stage trial for EDG-7500, an experimental ...

Investing.com -- Shares of Cytokinetics (NASDAQ: NASDAQ:CYTK) climbed 11% after Edgewise Therapeutics reported results for its treatment of hypertrophic cardiomyopathy (HCM), which led to a 28% ...

SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment and ...